A Study With Mirabegron 50 mg and 25 mg in Chinese Participants with Overactive Bladder

Trial Identifier: 178-MA-2295
Sponsor: Astellas Pharma China, Inc.
Start Date: January 2021
Primary Completion Date: March 2022
Study Completion Date: March 2022
Condition: Bladder Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China
China Chengdu, China
China Guangzhou, China
China Lanzhou, China
China Shanghai, China
China Suzhou, China
China Taiyuan, China
China Wuhan, China
China Wuxi, China
China Xi'an, China
China Zhengzhou, China
China, Hubei Wuhan, Hubei, China